NCT06501287 Postprandial Triglyceride Impact on Coronary Atherosclerosis in Non-Diabetic Patient in Sohag University Hospital
| NCT ID | NCT06501287 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fatma Madhy Eissa |
| Condition | Coronary Atheroscleroses |
| Study Type | OBSERVATIONAL |
| Enrollment | 160 participants |
| Start Date | 2024-05-01 |
| Primary Completion | 2024-12-25 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 160 participants in total. It began in 2024-05-01 with a primary completion date of 2024-12-25.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
INTRODUCTION Cardiovascular diseases, including coronary artery disease (CAD), are the leading cause of mortality worldwide. Despite remarkable advancements in diagnostic and therapeutic approaches, CAD continues to pose formidable challenges. Atherosclerosis, characterized by the deposition of lipids, inflammatory cells, and fibrous tissue within the arterial walls, is the fundamental pathology underpinning CAD. Atherosclerosis development and progression are closely intertwined with lipid metabolism, particularly elevated levels of low-density lipoprotein cholesterol (LDL-C) and reduced levels of high-density lipoprotein cholesterol (HDL-C) \*1+. However, emerging evidence suggests that postprandial triglyceride levels, the transient increase in triglycerides following a meal, may play a pivotal role in atherosclerotic processes \*2+. Postprandial hypertriglyceridemia has been linked to various cardiovascular risk factors, including inflammation, endothelial dysfunction, oxidative stress, and altered hemostasis \*3+. cardiovascular disease (CVD) causes death for 4 million subjects in Europe every year. It causes death for women \*2.2 million (55%)+ than men \*1.8 million (45%)+, and cardiovascular (CV) deaths under 65 years more prevalent in men (490 000 versus 193 000) \*4+. Endothelial dysfunction was the main cause of vascular atherosclerosis. The damage of Endothelium cause lipids and macrophages accumulation (mostly lowdensity lipoprotein) in vessel injury site \*5+. Lipids considered the major cause of atherosclerosis \*6+. The increase of blood cholesterol (especially LDL) considered the main cause of the disease. High levels of triglycerides could be independent risk factor for coronary artery disease (CAD), particularly in women. Although, it was suggested that high level of density lipoproteins (HDLs) can prohibit these risk factors. Extensive examinations showed that lipid decrease the prevention of CAD in primary and secondary cases \*7+. The level \> 90% of total glyceride and/or LDL and level \> 10% of HDL confirm dyslipidemia \*8+
Eligibility Criteria
Inclusion criteria includes CAD based on coronary angiography, laboratory and ECG evidence. Exclusion criteria: Patients with other co-morbidities diseases, such as liver and kidney disorders and thyroid diseases. Diabetic patients.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06501287 clinical trial?
This trial is open to participants of all sexes, studying Coronary Atheroscleroses. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06501287 currently recruiting?
Yes, NCT06501287 is actively recruiting participants. Contact the research team at fatma_mdhy_post@med.sohag.edu.eg for enrollment information.
Where is the NCT06501287 trial being conducted?
This trial is being conducted at Sohag, Egypt.
Who is sponsoring the NCT06501287 clinical trial?
NCT06501287 is sponsored by Fatma Madhy Eissa. The trial plans to enroll 160 participants.